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Background:  Vaccination  against  human  papillomavirus  (HPV)  to prevent  cervical  cancer  (CC)  primarily
targets  young  girls  before  sexual  debut  and  is  cost-effective.  We  assessed  whether  vaccination  with  the
HPV-16/18  AS04-adjuvanted  vaccine  added  to screening  remains  cost-effective  in  females  after  sexual
debut compared  to  screening  alone  in Belgium.  The  role  of  protection  against  non-HPV-16/18  was  also
investigated.
Methods:  A  published  Markov  cohort  model  was  adapted  to  Belgium.  The  model  replicated  the  natu-
ral history  of  HPV  infection,  the  effects  of  screening,  and  vaccination.  Vaccine  efﬁcacy  (VE) included
non-HPV-16/18  protection  based  on  the  PATRICIA  clinical  trial data.  Pre-  and  post-HPV  exposure  VE
were  differentiated.  Lifetime  vaccine  protection  was  assumed.  Input  data  were  obtained  from  literature
review,  national  databases  and  a Delphi  panel.  Costing  was  from  a healthcare  payer  perspective.  Costs
were  discounted  at 3%  and  effects  at  1.5%.  The  incremental  cost-effectiveness  ratio  (ICER)  per  quality-
adjusted  life-year  (QALY)  gained  and  the  number  of lesions  prevented  with  vaccination  from  age  12 to  40
was  evaluated.  The  speciﬁc  effect  of  non-HPV-16/18  protection  was  investigated.  Univariate  sensitivity
analysis  was  performed  on  key  variables.
Results:  The  model  estimated  that  vaccinating  a cohort  of  100,000  girls  at age  12  would  prevent  646 CC
cases  over  a  lifetime  (102  non-HPV-16/18)  with  an  ICER  of  D  9171/QALY.  Vaccinating  at  age  26 would
prevent  340  CC  cases  (40  non-HPV-16/18)  with  an  ICER  of  D  17,348/QALY  and  vaccinating  at age  40  would
prevent  146  CC  cases  (17  non-HPV-16/18)  with  an  ICER  of  D  42,847/QALY.  The  ICER  remained  under  the
highly  cost-effective  threshold  (1×GDP/capita)  until  age  33 years  and  under  the  cost-effective  threshold
(3×GDP/capita)  beyond  age  40.
Conclusion:  Extending  HPV  vaccination  to females  post-sexual  debut  could  lead  to  a substantial  reduction
in  CC-related  burden  and  would  be cost-effective  in Belgium.
 201  ©
. IntroductionWorldwide, cervical cancer is the third most common cancer
n women [1]. Although screening can reduce the incidence of and
ortality from cervical cancer, by detecting and allowing treatment
Abbreviations: CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CIS,
arcinoma in situ; GDP, gross domestic product; HPV, human papillomavirus; ICER,
ncremental cost-effectiveness ratio; QALY, quality-adjusted life-year; TVC, total
accinated cohort; VE, vaccine efﬁcacy.
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of pre-cancerous changes, cervical cancer remains an important
public health problem in Europe, with an estimated 31,000 cases
and 14,000 deaths in 2004 [2]. In Belgium, about 600 cases of cervi-
cal cancer occur annually according to Belgian Cancer Registry data
[3], and the estimated total annual cost of cervical cancer is D 6.5
million [4].
Human papillomavirus (HPV) is established as a causal factor
in cervical cancer, identiﬁed in 99.7% of cervical cancers world-
wide [5]. Vaccination against high-risk oncogenic serotypes of HPV
offers potential for primary prevention of cervical cancer [6]. Two
Open access under CC BY license.HPV vaccines are widely available, a quadrivalent vaccine against
HPV types 16, 18, 6 and 11 (GardasilTM,1 Merck/Sanoﬁ-Pasteur)
and a bivalent vaccine against HPV types 16 and 18 with the AS04
1 Gardasil is a trademark of Merck & Co. Inc.
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djuvant (Cervarix®,2 GlaxoSmithKline Vaccines). Clinical data have
emonstrated that both vaccines offer protection against oncogenic
on-vaccine HPV types [7–9]. The HPV-16/18 AS04-adjuvanted
accine (HPV-16/18 vaccine) however potentially offers a better
rotection against oncogenic non-vaccine HPV types than the HPV-
6/18/6/11 vaccine [10,11].
Current HPV vaccination programmes mainly target adoles-
ent girls, before the onset of sexual activity (sexual debut). In
elgium, HPV vaccination is recommended at age 12 years, with
 reimbursed catch-up programme to age 18 years [12]. Other
ountries have extended the catch-up programme to include young
omen; for example, Australia has extended the HPV vaccination
rogramme to girls and young women aged 12–26 years [13], and
he US also recommends vaccination up to age 26 years [14].
Cost-effectiveness analyses have been conducted for HPV vac-
ination programmes in girls aged 12 years for many countries
mong which are France [15] and Belgium [6,16]. Few economic
valuations of HPV vaccination in young adult and adult women,
ssessing catch up programmes, have been published. In 2010 a
eview identiﬁed only 8 publications on this topic [17]. The same
iterature query run in 2012, identiﬁed an additional 22 articles of
hich 5 articles evaluated catch-up vaccination programmes and
7 not discussing the topic. No speciﬁc evaluation, adapted to the
elgian setting, of the cost-effectiveness of vaccination after the
ecommended age at vaccination have been performed to date.
ealthcare decision-makers may  need information on the pro-
ected clinical impact and cost-effectiveness of HPV vaccination in
oung adult and adult women when deciding whether to imple-
ent or extend catch-up vaccination programmes in older age
roups.
In this paper, we present the results of a mathematical model
valuating HPV vaccination with a HPV-16/18 vaccine in addition
o current screening at different ages in Belgium compared with
creening alone from the perspective of the Belgian health care
ayer. We  also investigated the role of protection against non-HPV-
6/18 related lesions on the cost-effectiveness of the vaccine.
. Materials and methods
.1. Model design
This analysis used a previously published Markov model that
odels a cohort of women over a lifetime, reproducing the natural
istory of HPV infection, the effect of screening and the effect of HPV
accination [18]. Brieﬂy, a single cohort of girls (N = 100,000) enters
he model at age 12 or more and move throughout different stages
f the natural history of cervical cancer in yearly cycles governed by
he transition probabilities in each stage. The natural history in the
odel is modiﬁed by the effect of screening and vaccination in each
ycle. This model was adapted to include Belgian-speciﬁc settings
elated to screening and cost. This model does not take into account
he economy that could be derived from the reduction in antenatal
ospitalization, preterm deliveries and neo natal cares that can be
waited from the reduction in the number of conisation resulting
n the primary prevention of cervical dysplasias [19].
.2. Model inputsThe transition probabilities used in the model are shown in
able 1.
Whenever available, Belgian-speciﬁc data were used. However,
or parameters relating to the natural history of the disease (i.e.
2 Cervarix is a registered trademark of the GlaxoSmithKline group of companies. 31 (2013) 3962– 3971 3963
independent of treatment or screening) we used published data
from other countries, as these parameters were assumed to be
identical across countries.
The validity of the model was assessed by comparing the
age-speciﬁc cervical cancer incidence and deaths estimated by
the model without vaccination to the cervical cancer incidence
reported by the Belgian cancer registry.
2.2.1. Vaccine effectiveness
From the model construct, the vaccine effectiveness only applies
to the transition from no HPV to HPV. Vaccine effectiveness data
were derived from published clinical trials (Table 1). For women
before the age of sexual debut (pre-exposure to HPV), vaccine effec-
tiveness was  based on vaccine efﬁcacy reported for girls and women
who  were DNA-negative for the relevant HPV type at study entry
(Total Vaccinated Cohort [TVC] naïve cohorts) [7,39]. This popu-
lation was selected as representative of vaccine efﬁcacy among
girls and women  pre-HPV exposure. For women post-HPV expo-
sure, we used vaccine efﬁcacy reported from vaccine clinical trials
for women who were HPV DNA-negative regardless of serostatus
at baseline [7]. These data represent vaccine efﬁcacy against inci-
dent infection among women with and without previous infection
but without current infection. This population even though limited
to 25 years of age was  selected as the most representative among
available data for vaccination post-sexual debut, in whom the vac-
cine effect is limited to prevention of incident infection, and who
may  have had a previous infection that has cleared. The cut-off
age between pre- and post-exposure was set at 17 years, based on
the reported median age of ﬁrst sexual intercourse in industrialised
countries [20]. Vaccination before age 17 years was modelled using
the pre-exposure vaccine efﬁcacy, while vaccination after age 17
years was  modelled using the post-exposure efﬁcacy.
Overall vaccine effectiveness took into account efﬁcacy against
vaccine HPV types (HPV-16 and HPV-18), and protection efﬁcacy
against 10 other HPV types (HPV-31/33/35/39/45/51/52/56/58/59)
[7,8,22]. Data on efﬁcacy against each HPV type were combined
with the proportion of each HPV type within each lesion to estimate
overall expected vaccine effectiveness, calculated as follows:
VE =
∑
i
%HPVi × Vei
where VE is the vaccine effectiveness against a speciﬁc lesion;
i = HPV-16/18, HPV-31/33/35/39/45/51/52/56/58/59; %HPVi is the
frequency with which HPV type i occurs in a speciﬁc lesion; Vei is
the type-speciﬁc (i) vaccine efﬁcacy.
Vaccination was assumed to confer lifelong protection. In sce-
narios without protection against non-HVP-16/18, this component
of vaccine effectiveness was set at 0.
2.2.2. Costs
The analysis was performed from the perspective of the Belgian
healthcare payers, and therefore included direct medical costs only.
A two-round Delphi panel with six Belgian healthcare prac-
titioners estimated the average use of medical resources for
treatment of cervical intraepithelial neoplasia (CIN) of different
severities (grade 1 and grade 2/3), cervical cancer and the current
standard of Papanicolaou smear-based screening. Unit cost data
(in 2010 D ) obtained from Belgian healthcare tariffs [21] for each
resource were used to estimate the costs associated with the treat-
ment of each lesion and screening. This does not take into account
additional costs such as those related to pre-term deliveries for
conisation [22,19].
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Table 1
Input data.
Variable Base case valuea Reference
State: HPV Onc
HPV infection rate Yearly incidence of HPV Onc Due to lack of Belgian data, incidence is based
on  HPVonc incidence by age in France
estimated from HPV prevalence, progression to
CIN, HPV clearance and natural mortality [35]
HPV regression to No HPV Age dependent probabilities [36–38]
HPV progression to CIN1 0.05 [39]
HPV progression to CIN2/3 0 Spontaneous progression within 1 year,
assumed to be 0 (i.e. need at least 2 years to
develop CIN2/3)
State: CIN1 and CIN1 detected
CIN1 detected 0.67 [40]
CIN1 regression to No HPV 0.50 [41,42]
CIN1 progression to CIN2/3 0.12 [41]
CIN treatment practice and efﬁcacy 28% of CIN1 detected patients undergoing treatment; 95%
efﬁcacy of CIN1 treatment (patients returning to Normal
(No HPV) state after treatment)
Expert opinion
State: CIN2/3, persistent CIN2/3 and CIN2/3 detected
CIN2/3 regression to No HPV 0.267 [41]
CIN2/3 regression to CIN1 0 Assumption
CIN2/3 progression to persistent CIN2/3 0.128 [41]
CIN2/3 detected 0.75 [40]
Persistent CIN2/3 progression to cancer 0.0025 increase from 20 years to 40, 0.0025/8 increase
from 40 to 60; 0.0025/16 increase thereafter
Assumptions (no data available)
CIN2/3  treatment practice and efﬁcacy 96% of CIN2/3 detected patients undergoing treatment;
90% efﬁcacy of CIN2/3 treatment (patients returning to
Normal (No HPV) state after treatment)
Expert opinion
State: Cervical cancer
Cancer death with ICC Age-dependent
Cancer cured 19.0% [43]
State: Natural mortality
Death rates Overall death rate (age speciﬁc) [44]
Utilities
CIN1 detected 0.009376 (0.00750; 0.01125) [45–49]
CIN2/3 detected 0.009376 (0.00750; 0.01125) [45–49]
Cancer 0.273000 (0.21840; 0.32760) [45–49]
Cancer cured 0.062000 (0.04960; 0.07440) [45–49]
Vaccine effectiveness against HPV-related lesions in Belgium: Cervarix® Pre-exposure, TVC-naive
CIN1
HPV-16/18 distribution 20.8% [50]
Vaccine effectiveness HPV-16/18b 98% (88.4%; 100.0%) [51,7]
Non-HPV-16/18c 42.8% [50]
Vaccine effectiveness non-HPV-16/18 48% (28.9%; 61.9%) [28,7]
Total vaccine effectiveness CIN1 40.9% (30.8%; 47.3%)
CIN2/3
HPV-16/18 distribution 51.5% [50]
Vaccine effectiveness HPV-16/18 98% (88.4%; 100.0%) [51,7]
Non-HPV-16/18c 40.3% [50]
Vaccine effectiveness non-HPV-16/18 68% (45.7%; 82.4%) [7,8]
Total vaccine effectiveness CIN2/3 77.8% (63.9%; 84.7%)
Cervical cancer
HPV-16/18 distribution 77.5% [50]
Vaccine effectiveness HPV-16/18b 98% (88.4%; 100.0%) [51,7]
Non-HPV-16/18c 17.8% [50]
Vaccine effectiveness non-HPV-16/18 68% (45.7%; 82.4%) [7,8]
Total vaccine effectiveness cervical cancer 88.1% (76.7%; 92.2%)
Cervarix® Post-exposure, DNA-negative, regardless of serostatus
CIN1
HPV-16/18 distribution 20.8% [50]
Vaccine effectiveness HPV-16/18 89% (81.6%; 94.0%) [27]
Non-HPV-16/18c 42.8% [50]
Vaccine effectiveness non-HPV-16/18 34% (19.0%; 45.6%) [27,7]
Total vaccine effectiveness CIN1 33.1% (25.1%; 39.1%)
CIN2/3
HPV-16/18 distribution 51.5% [50]
Vaccine effectiveness HPV-16/18d 89% (81.6%; 94.0%) [27]
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Table 1 (Continued)
Variable Base case valuea Reference
Non-HPV-16/18c 40.3% [50]
Vaccine effectiveness non-HPV-16/18 47% (28.2%; 61.6%) [27,7]
Total vaccine effectiveness CIN2/3 64.7% (53.4%; 73.2%)
Cervical cancer
HPV-16/18 distribution 77.5% [50]
Vaccine effectiveness HPV-16/18d 89% (81.6%; 94.0%) [27]
Non-HPV-16/18c 17.8% [50]
Vaccine effectiveness non-HPV-16/18 47% (28.2%; 61.6%) [27,7]
Total vaccine effectiveness cervical cancer 77.4% (68.3%; 73.2%)
Cost data (D , 2010)
Regular screening negative pap 34 (27; 41) [21]
Regular screening + false positive 37 (29; 44)
Treatment CIN1 detected 657 (525; 788)
Treatment CIN2/3 detected 1616 (1293; 1939)
Cancer (Stage I–IV) 8190 (6552; 9828)
Vaccine cost (full course) 431 (345; 518)
Discount cost/outcomes 3.0%/1.5% (0%/0%; 5%/5%)
CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ; DNA, deoxyribonucleic acid; HPV, human papillomavirus; HPVonc, oncogenic human papillomavirus; ICC,
invasive cervical cancer; TVC, total vaccinated cohort.
a Lower value − upper value for univariate sensitivity analysis when appropriate.
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ib Pre-exposure vaccine efﬁcacy against HPV-16/18 assumed 98% against any lesi
c Non-vaccine oncogenic HPV types (HPV-31/33/35/39/45/51/52/56/58/59).
d Post-exposure vaccine efﬁcacy against HPV-16/18 conservatively assumed 89%
.3. Utility
Utility values for detected HPV lesions (CIN1, CIN2/3, cervical
ancer) were extracted from published literature (Table 1). We
ssumed that undergoing a pap test was associated with no utility
oss even though it may  be the case no study reported such utility
ecrement.
.4. Discounting
Based on the Belgian guidelines, costs were discounted at an
nnual rate of 3% and health beneﬁts at 1.5% [23,24]).
.5. Model outcomes
All analyses were run with a cohort of 100,000 girls aged 12
ears, followed over a lifetime (95 years). For each scenario, the
ncremental lifetime costs, QALY, cancer cases between a cohort
ndergoing vaccination and screening, and a cohort undergoing
creening alone were computed. The incremental cost and QALY
ere discounted at 3% and 1.5%, respectively while cervical cancer
ases were reported undiscounted. The ICER represents the ratio
etween the incremental costs and the incremental QALY.
.5.1. Base case
The base case compared two cohorts, one receiving HPV vacci-
ation and screening, and one receiving screening alone. Screening
lone (every 3 years from age 25 to 65 years for 59% of the pop-
lation [25]) was compared with the same screening plus HPV
accination with 80% vaccination coverage assumed. The vaccina-
ion scenarios were run with age at vaccination ranging from 12 to
0 years in increments of 2 years.
For each scenario, the model estimated the number of cervi-
al cancer cases, the number of quality-adjusted life-years (QALYs)
nd total cost. Based on these results, the incremental costs, QALY,
ervical cancer cases avoided and incremental cost-effectiveness
atios (ICER) were estimated for each vaccination scenario com-
ared with no vaccination. Two thresholds for cost-effectiveness
ere considered: very cost-effective (<1× Belgian gross domes-
ic product [GDP] per capita per QALY gained, i.e. D 32,200/QALY),
nd cost-effective (<3× Belgian GDP per capita per QALY gained,
.e. D 96,600/QALY). GDP per capita was taken from Internationale, as observed for CIN2+ [7].
st any lesion type, as observed for CIN1.
Monetary Fund data [26], mid-point of 2010 values at current and
constant prices rounded to 2 signiﬁcant ﬁgures.
All analyses were run with and without protection against non-
HPV-16/18.
2.5.2. Catch-up scenario
The number of incident cervical cancer and CIN2+ cases under
different catch-up scenarios was estimated over 40 years. Two
catch-up scenarios were assessed: vaccination from 12 to 18 and
from 12 to 25 years of age. For each the number of cervical cancer
cases was  summed over the 14 cohorts (12–25 years of age) either
with or without vaccination. The analysis was  conducted both with
and without protection against non-HPV-16/18.
2.6. Sensitivity analyses
One-way and probabilistic sensitivity analyses were conducted
to explore the effect on the results of uncertainty in the input val-
ues. Vaccine cost, treatment cost, utilities, and HPV incidence were
varied from 20% below to 20% above the base-case value. The dura-
tion of protection was  reduced to 25 years or 10 years without the
administration of a booster. Input parameters related to vaccine
effectiveness were varied by reported conﬁdence intervals [7,27],
capped at 100%. Discount rates of 0% and 5% were applied for both
costs and health outcomes, reﬂecting the range observed across
other countries’ health economic guidelines [23].
Probabilistic sensitivity analyses using @RISK software (Palisade
Corporation, US) were conducted to estimate conﬁdence intervals
around the ICER for vaccination at 15, 20, 25, 30, 35 or 40 years of
age. In these analyses, distributions were assigned to each variable
(Table 2).
When range data were available, normal distribution was
selected, deriving the standard deviation from the observed range
and mean as the base-case value. When no range data were avail-
able, a uniform distribution from 80% to 120% of base-case value
limited to 100% was applied. For transition probabilities, utilities
and vaccine efﬁcacy data, the distributions were limited between
0 and 1. Ten thousand simulations were run with each vari-
able sampled from the distribution for each age at vaccination. A
non-parametric 80% conﬁdence interval was derived from these
simulations.
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Table 2
Inputs for multivariate probabilistic sensitivity analysis.
Variable Distribution Distribution parameters Reference
Transition probabilities
Age-dependent mortality data Uniform distribution Age-dependent Assumption
Age-dependent HPV incidence Uniform distribution Age-dependent Assumption
HPV  Onc to CIN1 progression Normal distribution 0.05 (SD 0.009) [39]
Regression from CIN1 to No HPV Normal distribution 0.5 (SD 0.145) [41,42]
CIN1 Onc to CIN2/3 progression Normal distribution 0.12 (SD 0.021) [41]
Regression from CIN2/3 to No HPV Normal distribution 0.267 (SD0.058) [41]
Proportion CIN1 Onc treated Uniform distribution 0.224–0.336 Assumption
CIN1 treatment success Uniform distribution 0.9–1 Assumption
CIN2/3 progress to persistent CIN2/3 Uniform distribution 0.102–0.154 Assumption
Proportion CIN2/3 treated Uniform distribution 0.768–1 Assumption
CIN2/3 treatment success Uniform distribution 0.72–1 Assumption
Cervical cancer to death Uniform distribution 0.066–0.098 Assumption
Cervical cancer to cured Uniform distribution 0.152–0.228 Assumption
Utility data
No HPV Fix (1) 1 Assumption
HPV  Fix (1) 1 Assumption
CIN1  Fix (1) 1 Assumption
CIN2/3 Fix (1) 1 Assumption
Death Fix (0) 0 Assumption
Disutility of CIN1 detected Uniform distribution 0.010–0.015 Assumption
Disutility of CIN2/3 detected Uniform distribution 0.008–0.011 Assumption
Disutility of Cancer Uniform distribution 0.218–0.328 Assumption
Disutility of cancer cured 0.050–0.074 Assumption
Screening effectiveness
CIN1 detected Normal distribution 0.67 (SD 0.045) [40]
CIN2/3 detected 0.75 (SD 0.045) [40,7]
Percentage estimated pos Pap smear Uniform distribution 0.044–0.066 Assumption
Vaccine effectiveness
Pre-exposure
Vaccine effectiveness against HPV-16/18 Normal distribution 0.98 (SD 0.045) [51]
Non-HPV-16/18 CIN2/3 and CCa Normal distribution 0.68 (SD 0.092) [8]
Non-HPV-16/18 CIN1a Normal distribution 0.48 (SD 0.084) [28]
Post-exposure
Vaccine effectiveness against HPV-16/18 Normal distribution 0.89 (SD 0.045) [27]
Non-HPV-16/18 CIN2/3 and CCa Normal distribution 0.47 (SD 0.084) [27]
Non-HPV-16/18 CIN1a Normal distribution 0.34 (SD 0.067) [27]
HPV type and CIN distributions
Proportion of HPV-16/18 in CC Normal distribution 0.775 (SD 0.1735) [50]
Proportion of HPV-16 and -18 among CIN1 Uniform distribution 0.166–0.250 Assumption
Proportion of HPV-16 and -18 among CIN2/3 Uniform distribution 0.412–0.618 Assumption
Cost  data
HPV-16/18 vaccine Uniform distribution D 324–D 539 Assumption
HPV-16/18 vaccine booster cost Uniform distribution Fix at one-third of the vaccine price Assumption
C irus; S
3
3
t
i
f
3
c
c
vC, cervical cancer; CIN, cervical intraepithelial neoplasia; HPV, human papillomav
a Non-vaccine oncogenic HPV types (HPV-31/33/35/39/45/51/52/56/58/59).
. Results
.1. Model validation
The cervical cancer incidence modelled without vaccination ﬁt-
ed the reported age-dependent cervical cancer incidence observed
n Belgium between 2001 and 2003. Similar results were obtained
or cervical cancer deaths.
.2. Base caseTable 3 shows the base-case incremental costs, QALY, cervical
ancers avoided and ICER for vaccination with the HPV-16/18 vac-
ine compared with no vaccination in Belgium for different ages at
accination with and without protection against non-HPV-16/18.D, standard deviation.
At age 12 years, with protection against non-HPV-16/18, vac-
cination was  highly cost-effective (ICER D 9171/QALY), and was
projected to save 646 cases of cervical cancer per 100,000 girls
vaccinated. As age at vaccination increased the number of cases
of cervical cancer avoided and the cost-effectiveness of vaccination
decreased (ICER increased). However, vaccination at age 40 years
was  still projected to save 146 cases of cervical cancer per 100,000
females vaccinated.
As expected, the cost-effectiveness and number of cases of cervi-
cal cancer prevented were both improved when protection against
non-HPV-16/18 was  included. Protection against non-HPV-16/18
resulted in an additional 102 cervical cancers prevented for vacci-
nation at 12 years of age to 17 cervical cancer cases for vaccination
at 40 years of age and reduced the discounted ICER by D 2456 or
D 6181, respectively.
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Table 3
Modelled effect of vaccination for a single age-cohort (n = 100,000) of 12–40-year-old females in Belgium with lifetime vaccination protection compared with screening alone
(with  and without accounting for cross protection).
Age (y) Incremental cost vs. screening
alone (discounted 3%)
Incremental QALY vs. screening
alone (discounted 1.5%)
Total cervical cancer cases
avoided vs. screening alone
ICER (D /QALY)
Impact on HPV-16/18-related lesions and beyond (with protection against non-HPV-16/18)
12  27,118,169D 2957 −646 9171
14  26,963,497D 2942 −628 9164
16  27,042,960D 2849 −597 9492
18  28,437,184D 2339 −482 12,156
20  28,709,073D 2222 −450 12,923
22  29,109,872D 2096 −418 13,892
24  29,707,625D 1926 −380 15,428
26  30,209,689D 1741 −340 17,348
28  30,661,509D 1567 −303 19,571
30  31,365,112D 1368 −264 22,920
32  31,870,671D 1185 −228 26,903
34  32,218,222D 1040 −200 30,975
36  32,599,077D 926 −178 35,201
38  32,754,699D 837 −160 39,126
40  32,859,034D 767 −146 42,847
Impact on HPV-16/18-related lesions alone (without protection against non-HPV-16/18)
12  28,916,356D 2487 −544 11,627
14  28,825,167D 2474 −529 11,649
16  28,931,404D 2396 −502 12,075
18  29,725,188D 2051 −423 14,490
20  29,993,099D 1949 −395 15,389
22  30,374,664D 1840 −367 16,511
24  30,929,007D 1693 −334 18,272
26  31,273,112D 1533 −300 20,400
28  31,588,949D 1381 −268 22,868
30  32,231,791D 1209 −233 26,670
32  32,600,352D 1048 −202 31,121
34  32,834,653D 920 −177 35,671
36  33,192,372D 820 −158 40,483
38  33,259,490D 741 −142 44,866
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CER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; y, year
Fig. 1 shows the projected ICER with and without cross protec-
ion, together with cost-effectiveness thresholds.
When cross protection was included, the ICER remained under
he ‘very cost-effective’ threshold (1×GDP per capita, i.e. D 32,200)
ntil age 35 years, and under the ‘cost-effective’ threshold (3×GDP
er capita, i.e. D 96,600) beyond age 40 years (the highest age
odelled). Without protection against non-HPV-16/18, the ICER
emained below the ‘very cost-effective’ threshold until age 33
ears, and was still below the ‘cost-effective’ threshold beyond age
0 years.
.3. Catch-up
Fig. 2 shows the incident cases predicted by the model for
ohorts from 12 to 25 years of age over 40 years post-vaccination.
Extending catch-up from 18 to 25 years resulted in additional
ases prevented and a faster decrease in cervical cancer post-
accination.
.4. Sensitivity analyses
The results of the one-way sensitivity analyses are shown in
ig. 3A–F.
The discount rate was the most inﬂuential factor. With a dis-
ount rate of 5% the ICER was always above the threshold of
×GDP/capita (D 32,200), whereas with a discount rate of 0% the
ge at which the ICER crossed the threshold of 1×GDP/capita was
bove 40 years. The other factors tested in sensitivity analyses (vac-
ine price, vaccine effectiveness, treatment costs, utility values HPV
ncidence and vaccine duration of protection) had relatively small
ffects (almost no effect for treatment cost and utility value) on−129 49,028
the age at which the ICER crossed the cost-effectiveness threshold.
The age at which the ICER crossed the threshold of 1×GDP/capita
(D 32,200) was 26–35 years for the lower bound values and 35–38
years for the upper bound values.
Fig. 3H shows the results of the probabilistic sensitivity analy-
sis. These ﬁndings indicate that HPV vaccination would be expected
to remain cost-effective for vaccination up to 25–30 years of age,
accounting for the overall uncertainty around the model input
parameters. The upper bound of the ICER conﬁdence interval was
below the very cost-effective threshold for vaccination at age 25
years and slightly above the threshold for vaccination at age 30
years.
4. Discussion
The modelling results presented here show that screening plus
vaccination against HPV using the HPV-16/18 vaccine at age 12
years, in Belgium, would save 646 cases of cervical cancer over the
lifetime of a 100,000 girl cohort, compared with screening alone,
and would be highly cost-effective (estimated ICER D 9171/QALY).
These results are consistent with other cost-effectiveness evalua-
tions for Belgium for a vaccination of 12 years old with base case
estimates of D 10,546 [16] and D 32,665 [25] for a quadrivalent vac-
cine for a vaccine protecting against HPV-16/18. The higher value
from Thiry et al. is driven by an assumed duration of protection
of 15 years instead of lifetime and lower vaccine efﬁcacy. If pro-
tection against non-vaccine HPV types was  not included in our
analysis, the projected results were slightly less favourable, with
vaccination projected to save 544 cases of cervical cancer at an
ICER of D 11,627/QALY. Both with and without protection against
non-vaccine types, the projected number of cases of cervical cancer
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vig. 1. Impact of age at vaccination on ICER and number of cervical cancer cases a
ross  domestic product (D 32,200 for Belgium); ICER, incremental cost-effectivenes
revented and the cost-effectiveness of vaccination progressively
eclined as age at vaccination increased. However, vaccination was
till highly cost-effective in young adult and adult women. At a
hreshold for cost-effectiveness of 1× Belgian GDP/capita per QALY
i.e. D 32,200), vaccination remained cost-effective up to age 35
ears with protection against non-vaccine types, or up to age 33
ears without protection against non-vaccine types. At a thresh-
ld for cost-effectiveness of 3× Belgian GDP/capita (i.e. D 96,600),
accination was cost-effective beyond the age of 40 years with
r without protection against non-vaccine types. The projected
umber of cervical cancer cases prevented by protection against
on-vaccine types was larger for vaccination at age 12 years com-
ared with vaccination at age 40 years (102 and 17 additional
ases prevented, respectively). However, the impact on the ICER
as larger for vaccination at older ages. This is due to the costs
ssociated with cases prevented at different ages. At ages above 40
ears proportionally more of the costs prevented relate to cancer,
hile in younger girls a greater proportion of the costs prevented
elate to screening costs, which are lower than cancer costs. Thus,
he cost averted for each case prevented will tend to be higher in
lder age cohorts, resulting in a larger impact of protection against
on-vaccine types on ICER for vaccination at older ages. Sensitiv-
ty analyses indicated that the results were robust to variations
n the input parameters. To our knowledge, this study is the ﬁrst
o evaluate HPV vaccination in young adult and adult women in
elgium.
Recent clinical trial data have reported that the HPV-16/18 vac-
ine has protection efﬁcacy against 10 non-vaccine HPV types and
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ig. 2. Yearly incident cervical cancer cases in the cohorts over time for three vaccina
accination from 12 to 25 years of age), both with and without cross protection. CC, cervi (with and without protection against non-HPV-16/18). CC, cervical cancer; GDP,
; QALY, quality-adjusted life-year.
that important vaccine efﬁcacy was observed irrespective of HPV
DNA status and serostatus [8,27,28]. The present study is the ﬁrst to
investigate the effect of this protection against non-HPV-16/18 data
on the cost-effectiveness of HPV vaccination in young adult and
adult women. Our results suggest that including protection against
non-vaccine HPV types increased the projected number of cervi-
cal cancer cases prevented and improved the cost-effectiveness of
adding vaccination to screening.
Our ﬁndings indicate that extending HPV vaccination pro-
grammes beyond age 12 years could produce substantial additional
health beneﬁts, and that HPV vaccination with the HPV-16/18 vac-
cine would remain cost-effective in adult women up to the age of 33
years to over 40 years (depending on the cost-effectiveness thresh-
old and whether protection against non-HPV-16/18 is included) in
Belgium. This is consistent with other reports even though adapted
to other country speciﬁc settings, that extending HPV vaccina-
tion beyond young girls may  be effective and cost-effective. In the
Netherlands, an evaluation using a Markov model found that HPV
vaccination remained generally cost-effective in women up to age
25 years [29], and some countries such as Australia [13] and the US
[14] already recommend HPV vaccination up to age 26 years. Adult
women  remain at risk of HPV infection from new sexual relation-
ships, and the protective effect of HPV vaccination against cancer
may  be seen more quickly in adult women than after vaccination
of adolescent girls [30]. Our analysis showed that the extension of
catch-up cohorts would be expected to produce a faster reduction
in cervical cancer. Rapid clinically measurable reductions in lesion
incidence have been observed soon after HPV vaccine introduction
403530250
-up time (years)
12 to 18 yoa vaccinated + CP
12 to 18 yoa vaccinated
tion scenarios (no vaccination, 80% catch up from 12 to 18 years of age and 80%
cal cancer; CP, protection against non-HPV-16/18; yoa, years of age.
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tig. 3. (A–G) One-way sensitivity analyses; (H) probabilistic sensitivity analyses (m
ntervals). GDP, gross domestic product (D 32,200 for Belgium); HPV, human papillo
n Australia, where recent data showed a signiﬁcant decrease in
igh-grade cervical abnormalities within 3 years of the introduc-
ion of HPV vaccination for girls and women aged 12–26 years [13].
The strengths of our model include its simplicity, transparency
nd adaptability to reﬂect country-speciﬁc epidemiology and dis-
ase management patterns, in this case for Belgium. It has already
een applied to economic evaluations of HPV vaccination in a range
f countries including Chile, Finland, Ireland, Poland, Taiwan and
rance [18,31,15]. The present results apply to Belgium, but could
lso be relevant to other countries with similar cervical cancer man-
gement and HPV epidemiology.
Our model has limitations. It is not a transmission dynamic
odel and therefore cannot capture indirect beneﬁts such as herd
rotection, which may  underestimate the potential beneﬁts of pro-
ection against non-HPV-16/18. On the other hand, our model
annot account for the existing herd effect on the girls included
n the catch-up and thus may  overestimate cost-effectiveness for
he additional catch-up cohort. The herd effect across age cohorts
ay, however, be more limited for HPV than for other viruses
uch as pertussis or inﬂuenza [32]. In addition, the model does
ot account for any expected effects of HPV vaccination on other
PV-associated cancers [33] or neonatal morbidity and mortality,
hich would underestimate vaccine cost-effectiveness [34]. Also
he input data are mainly based on a pre-vaccination situation. The
mplementation of the vaccine worldwide may  have an impact on,
.g. disease management or a change in HPV incidence from herd
ffect which may  also impact the cost-effectiveness of vaccinating
he new cohorts.alue of ICER accounting for protection against non-HPV-16/18 and 80% conﬁdence
rus; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
We  assumed vaccine coverage of 80%. As we used a static
model, the vaccine coverage rate does not affect the ICER estimate,
although it could affect the estimate of the absolute numbers of
lesions prevented.
The results presented here remain a modelling exercise, and are
yet to be conﬁrmed by real-world data from long-term follow-up
studies. However, such data may  be several years away, whereas
decisions about vaccination programme implementation must be
made in the near term. Our model offers a valuable method of esti-
mating the potential clinical and economic beneﬁts of extending
HPV vaccination to young adult and adult women.
5. Conclusions
The results presented here indicate that extending HPV vacci-
nation with the HPV-16/18 vaccine, in combination with screening,
to adult and young adult women  post-sexual debut could provide a
substantial reduction in cervical cancer disease burden in Belgium,
compared with screening alone. HPV vaccination with the HPV-
16/18 vaccine is projected to be cost-effective in women  up to age
33–40 years.
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